Background <p>Blinatumomab, inotuzumab or autologous anti-CD19 chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, tumor escape through antigenic modulation accounts for almost 40% of subsequent relapses. Multi-antigen targeting strategies should be developed, and it is urgent to identify new targets.</p> Methods <p>We investigated the extensive immunophenotyping of 13…
Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALL
Journal for ImmunoTherapy of Cancer | | Grain, A., Ollier, J., Le Calvez, B., Guiet, E., Thomas, C., Couec, M.-L., Camuset, M., Rialland, F., Eveillard, M., Scotet, E., Clemenceau, B.
Topics: blood-cancer
Read the full article at Journal for ImmunoTherapy of Cancer